Screening Volunteers for Clinical Trials
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01375530|
Recruitment Status : Recruiting
First Posted : June 17, 2011
Last Update Posted : August 15, 2018
- The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health needs healthy volunteers for vaccine clinical trials. These trials will allow researchers to study vaccines and injection devices. These studies will also allow researchers to understand the immune system and how vaccines work. In this protocol, researchers will screen healthy volunteers for these future trials.
- To screen healthy volunteers for clinical trials at the NIAID.
- Healthy people between 18 and 70 years of age. They must be available to take part in clinical trials and be able to provide blood for research studies.
- Screening for a clinical trial may begin several months before the vaccine clinical trial begins.
- Volunteers will be screened with a physical exam and medical history. They may also answer questions about sexual activity and drug use.
- Volunteers will provide blood samples and possibly urine samples. They may have other tests as needed for the study.
- Volunteers will not receive any treatment in this screening trial....
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||3000 participants|
|Official Title:||VRC 500:Screening of Volunteers for Clinical Trials of Investigational Products and Licensed Products Evaluated for Research Purposes|
|Study Start Date :||June 16, 2011|
- To screen subjects for their eligibility to participate in clinical trials ofinvestigational products or licensed products being evaluated for research purposes. [ Time Frame: Ongoing ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01375530
|Contact: Ingelise Gordon, R.N.||(301) firstname.lastname@example.org|
|United States, Georgia|
|Hope Clinic - Emory Vaccine Ctr||Recruiting|
|Decatur, Georgia, United States, 30030|
|Contact: Srilatha Edupuganti, M.D. 404-712-1434 email@example.com|
|United States, Maryland|
|University of Maryland, Baltimore||Recruiting|
|Baltimore, Maryland, United States, 21201-1595|
|Contact: Monica McArthur, Ph.D 410-706-0329 firstname.lastname@example.org|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: VRC Clinic 301-451-8715 email@example.com|
|United States, Pennsylvania|
|Hospital of the University of Pennsylvania||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104-6056|
|Contact: Pablo Tebas 215-349-8092 firstname.lastname@example.org|
|Principal Investigator:||Martin R Gaudinski, M.D.||National Institute of Allergy and Infectious Diseases (NIAID)|